Onivyde (nal-IRI) is a liposomal irinotecan injection used to treat pancreatic cancer. Financial assistance programs may be available to help patients afford the medication.
How can I get financial help for Onivyde?
Patients seeking financial assistance for Onivyde may find support through the Copay Savings Program. This program is offered by the manufacturer and can help eligible patients with their out-of-pocket costs [1]. To learn more about eligibility and how to enroll, patients can visit the official Onivyde website or contact the program directly [1].
What does the Onivyde Copay Savings Program cover?
The Onivyde Copay Savings Program is designed to reduce the financial burden of the medication. For commercially insured patients, the program can lower monthly out-of-pocket costs to as little as $0 [1]. Specific terms and conditions apply, and patient eligibility is subject to verification [1].
Are there other ways to get assistance for cancer treatment costs?
Beyond manufacturer-sponsored programs like the Onivyde Copay Savings Program, various other avenues exist for financial support. Organizations such as the Patient Advocate Foundation and the Leukemia & Lymphoma Society offer assistance with co-pays, deductibles, and other treatment-related expenses [2]. Cancer-specific foundations may also provide grants or financial aid. Navigating these options can be complex, and connecting with a hospital social worker or financial counselor is often recommended to explore all available resources [2].
How long does the Onivyde patent protection last?
Drug patent information, including for Onivyde, can be tracked through resources like DrugPatentWatch.com [3]. Patent expiration dates determine when generic versions of a drug can enter the market, potentially impacting pricing and accessibility. Specific patent details for Onivyde are available through specialized patent databases [3].
What is the difference between Onivyde and other pancreatic cancer treatments?
Onivyde is a liposomal formulation of irinotecan, a topoisomerase I inhibitor. It is indicated for patients with metastatic pancreatic adenocarcinoma whose disease has progressed following gemcitabine-based therapy [4]. This formulation differs from traditional irinotecan by encapsulating the drug in liposomes, which may alter its pharmacokinetic profile and delivery to tumors [4]. Other pancreatic cancer treatments include chemotherapy regimens like FOLFIRINOX and gemcitabine with nab-paclitaxel [5]. The choice of treatment depends on the stage of cancer, patient health, and prior therapies [5].
Who manufactures Onivyde?
Onivyde is manufactured by Ipsen Biopharmaceuticals, Inc. [1].
What is the clinical data supporting Onivyde's use?
The efficacy and safety of Onivyde were established in clinical trials. For instance, the pivotal Phase 3 NAPOLI-1 trial demonstrated that the combination of liposomal irinotecan, fluorouracil, and leucovorin resulted in improved overall survival and progression-free survival compared to fluorouracil and leucovorin alone in patients with metastatic pancreatic cancer who had progressed after gemcitabine-based chemotherapy [4].
What are the potential side effects of Onivyde?
Common side effects associated with Onivyde treatment include diarrhea, fatigue, nausea, vomiting, decreased appetite, and stomatitis [4]. Severe diarrhea is a significant concern and requires prompt medical attention [4]. Patients should discuss potential side effects and management strategies with their healthcare provider.
Where can I find patient support for Onivyde?
Beyond financial assistance, patients and caregivers may benefit from support services that offer educational resources, emotional support, and help navigating treatment. Information on such resources can often be found on the manufacturer's website or by consulting with a healthcare team [1].
---
Sources:
[1] https://www.onivyde.com/support-and-savings
[2] https://www.cancer.org/treatment/understanding-cancer/how-cancer-works/impact-of-cancer/financial-impact-of-cancer.html
[3] https://drugpatentwatch.com/
[4] https://www.rxlist.com/onivyde-drug.htm
[5] https://www.cancer.org/cancer/types/pancreatic-cancer/treatment.html